2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoic acid: a potent antioxidant [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 9951955 |
| SCHEMBL ID | 580229 |
| MeSH ID | M0510006 |
| Synonym |
|---|
| 2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoic acid |
| SCHEMBL580229 |
| 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)benzylamino)benzoic acid |
| 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzylamino)benzoic acid |
| 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoic acid |
| 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzylamino) benzoic acid |
| neu2000 |
| neu-2000 |
| 2-hydroxy-5-[2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino]-benzoic acid |
| CS-0025740 |
| nelonemdaz |
| HY-106408 |
| 640290-67-1 |
| SB17041 |
| nelonemdaz [inn] |
| benzoic acid, 2-hydroxy-5-(((2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)methyl)amino)- |
| TP6PKI8CQP , |
| unii-tp6pki8cqp |
| neu-2000-kl |
| 2-hydroxy-5-((2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)methylamino)benzoic acid |
| 2-hydroxy-5-[[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methyl]amino]benzoic acid |
| MS-26284 |
| AKOS040742280 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aspirin | benzoic acids; phenyl acetates; salicylates | anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| sulfasalazine | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| fluorobenzenes | monofluorobenzenes | NMR chemical shift reference compound | 2007 | 2018 | 12.8 | high | 1 | 0 | 0 | 5 | 4 | 0 | |
| lithium carbonate | carbonate salt; lithium salt | antimanic drug | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| n-methylaspartate | amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound | neurotransmitter agent | 2007 | 2009 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 | |
| salicylates | monohydroxybenzoate | plant metabolite | 2007 | 2018 | 12.8 | high | 1 | 0 | 0 | 5 | 4 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Disease | 0 | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| ALS - Amyotrophic Lateral Sclerosis | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Amyotrophic Lateral Sclerosis | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Anoxemia | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Apoplexy | 0 | 2010 | 2018 | 10.0 | low | 1 | 0 | 0 | 1 | 1 | 0 | |
| Brain Ischemia | 0 | 2007 | 2018 | 12.3 | medium | 1 | 0 | 0 | 2 | 1 | 0 | |
| Cerebral Infarction, Middle Cerebral Artery | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Cerebral Ischemia | 0 | 2007 | 2018 | 12.3 | medium | 1 | 0 | 0 | 2 | 1 | 0 | |
| Disease Models, Animal | 0 | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 | |
| Hypoxia | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Infarction, Middle Cerebral Artery | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Injuries, Spinal Cord | 0 | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Spinal Cord Injuries | 0 | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Stroke | 0 | 2010 | 2018 | 10.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Article | Year |
|---|---|
| Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial. Trials, , Jul-13, Volume: 19, Issue:1 | 2018 |